Company Profile
Inhibikase Therapeutics Stock Price, News & Analysis
- Ticker:
- IKT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.45 USD (-0.41%)
Close
Last updated: August 11, 2026
224M USD
Market cap
Why the stock is moving
The latest monitored company update is “Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity.” The corresponding closing-price reaction is not yet available.
Company overview
Pulmonary Hypertension Company
Inhibikase Therapeutics develops IKT-001 for pulmonary arterial hypertension.
IKT-001
IKT-001 is a once-daily oral prodrug of imatinib intended to retain pulmonary vascular activity while improving gastrointestinal tolerability and long-term usability.
IMPROVE-PAH
The global Phase 3 IMPROVE-PAH study uses a seamless two-part design. Part A evaluates pulmonary vascular resistance, while Part B evaluates six-minute walk distance at 24 weeks.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inhibikase Therapeutics (IKT)?
Inhibikase Therapeutics (IKT) most recently closed at 2.45 USD, a -0.41% move versus the previous session.
What is the market cap of Inhibikase Therapeutics (IKT)?
Inhibikase Therapeutics currently has a market capitalization of 224M USD on BioPharmSignal.
What does Inhibikase Therapeutics do?
Pulmonary Hypertension Company Inhibikase Therapeutics develops IKT-001 for pulmonary arterial hypertension. IKT-001 IKT-001 is a once-daily oral prodrug of imatinib intended to retain pulmonary vascular activity while improving gastrointestinal tolerability and long-term usability. IMPROVE-PAH The global Phase 3 IMPROVE-PAH study uses a seamless two-part...
On which exchange is IKT stock listed?
Inhibikase Therapeutics (IKT) is associated with NASDAQ, United States, Biopharma.
What is IKT-001?
Pulmonary Hypertension Company Inhibikase Therapeutics develops IKT-001 for pulmonary arterial hypertension.
Which conditions is Inhibikase Therapeutics targeting with IKT-001?
Pulmonary Hypertension Company Inhibikase Therapeutics develops IKT-001 for pulmonary arterial hypertension. IKT-001 IKT-001 is a once-daily oral prodrug of imatinib intended to retain pulmonary vascular activity while improving gastrointestinal tolerability and long-term usability. IMPROVE-PAH The global Phase 3 IMPROVE-PAH study uses a seamless two-part...
What is IMPROVE-PAH?
IMPROVE-PAH The global Phase 3 IMPROVE-PAH study uses a seamless two-part design.
What is imatinib?
IKT-001 IKT-001 is a once-daily oral prodrug of imatinib intended to retain pulmonary vascular activity while improving gastrointestinal tolerability and long-term usability.